TEVA...por que te vas?

Click sobre imagen para ampliar

 By
Thomas Gryta 
DOW JONES
NEWSWIRES 

NEW YORK

Teva Pharmaceutical Industries Ltd. (TEVA), the biggest generic drug company in the U.S. market, is leaving the industry's lobbying group at the end of June.

In a letter to the Generic Pharmaceutical Association, the Israel-based company said it would advocate for its interests without the group, which it said wasn't meeting its potential.

"Unfortunately, as it is c structured, GPhA cannot appropriately reflect the policy priorities or marketplace realities of Teva," William Marth, president and chief executive of Teva North America, wrote in a letter Thursday.

GPhA officials didn't respond to a request for comment. Marth was chairman of the group until February.

Teva's planned withdrawal from the organization comes in the wake of recently passed healthcare overhaul that has changed the environment for the generics industry. The overhaul will increase patient access and side-stepped a proposed ban on patent-related court settlements. But it also gave branded companies a lucrative 12-year period of exclusivity on biologic drugs before a biosimilar--akin to a generic for the complex protein therapies--could be sold.

Ver